Allosteros Therapeutics, Inc. is a startup based in the United States.
Allosteros Therapeutics, Inc. is a company headquartered in the United States.
Allosteros Therapeutics was a drug discovery company developing selective small-molecule inhibitors of the Ca2+-dependent kinase CaMKII to address cardiovascular disease. Its CaMKII inhibitors demonstrated preclinical proof-of-concept for atrial fibrillation and ventricular arrhythmia by normalizing calcium homeostasis implicated in heart failure.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.